CRISPR Therapeutics AG
4.27 %
-37.15 %
Yet to be announced
Company Overview
CRISPR Therapeutics AG is a gene editing company focused on developing transformative gene-based medicines for serious diseases. The company's primary focus is on developing treatments using its CRISPR/Cas9 gene-editing platform, which enables precise, directed changes to genomic DNA. Their lead product, exa-cel (formerly known as CTX001), is being developed for the treatment of transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD).
Revenue Sources
PassCRISPR Therapeutics' revenue primarily comes from collaboration agreements and research grants for the development of gene-based therapeutic treatments. The company's business model and revenue sources are focused on legitimate medical research and development, which are halal activities aimed at treating serious diseases.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| March 31, 2025 | $865,000 | $149.29m | - | - | 0.00% | 0.00% |
| Dec. 31, 2024 | $35.69m | $100.28m | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $602,000 | $110.73m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $517,000 | $151.78m | - | - | 0.00% | 0.00% |
Based on the financial data provided for the last four quarters, CRISPR Therapeutics shows zero interest income and zero interest expense. The company appears to be operating without significant interest-bearing debt or interest-generating investments. However, since the company is still primarily in R&D mode and not yet in its mature operational phase, we should not apply the standard interest ratio tests at this time.
Operational Ethics
PassAfter reviewing available information from SEC filings and company materials, there is no evidence of current material associations with entities involved in human rights violations. The company's primary operations and research facilities are located in Switzerland and the United States.
Comments